10.4 C
New York
Friday, April 19, 2024
HomeNews
News

Comment by Pharmboy

By Single Comment
0
7
psw-placeholder
psw-placeholder

View Single Comment

  1. Pharmboy
    April 2nd, 2014 at 3:31 pm

    CYTK – damn those premiums are high.  I would try the May 10/15 BCS for 1.25.  They are expecting to release theri Phase 2 data at a neuro conference.   There is a lot riding on those data, and while they let the trial proceed unchanged and the wording says 'improvement', I guarentee they do not know who is on drug and who is not.  This is a controlled trial. 

    Their Phase 2a trial:

    Cytokinetics announced results from our Evidence of Effect clinical trial evaluating tirasemtiv in patients with myasthenia gravis in November 2012 and presented at the American Academy of Neurology (AAN) Annual Meeting in March 2013. This clinical trial was a double-blind, randomized, three-period crossover, placebo-controlled, pharmacokinetic and pharmacodynamic study of tirasemtiv in patients with generalized MG. The primary objective of this trial was to assess the effects of tirasemtiv on various measures of muscle strength, muscle fatigue and pulmonary function. In the trial, at six hours after dosing, improvements (i.e., decreases) in the Quantitative MG score (QMG) were related to the tirasemtiv dose in a statistical significant manner. Both the 250 mg and 500 mg single oral doses of tirasemtiv studied in this Phase IIa clinical trial were well-tolerated.

    Hence, I like my spread with a risk/reward of 4:1.



Stay Connected

157,350FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

Load more

Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW) nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

Contact us: support@philstockworld.com

© Copyright - PSW, LLC.

2024